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Abstract Background Dietary electrolytes inﬂuence
blood pressure, but their effect on clinical outcomes
remains to be established. We examined sodium and
potassium intake in relation to cardiovascular disease
(CVD) and mortality in an unselected older population.
Methods A case–cohort analysis was performed in the
Rotterdam Study among subjects aged 55 years and over,
who were followed for 5 years. Baseline urinary samples
were analyzed for sodium and potassium in 795 subjects
who died, 206 with an incident myocardial infarction and
181 subjects with an incident stroke, and in 1,448 randomly
selected subjects. For potassium, dietary data were addi-
tionally obtained by food-frequency questionnaire for 78%
of the cohort. Results There was no consistent association
of urinary sodium, potassium, or sodium/potassium ratio
with CVD and all-cause mortality over the range of intakes
observed in this population. Dietary potassium estimated
by food frequency questionnaire, however, was associated
with a lower risk of all-cause mortality in subjects initially
free of CVD and hypertension (RR = 0.71 per standard
deviation increase; 95% conﬁdence interval: 0.51–1.00).
We observed a signiﬁcant positive association between
urinary sodium/potassium ratio and all-cause mortality, but
only in overweight subjects who were initially free of CVD
and hypertension (RR = 1.19 (1.02–1.39) per unit). Con-
clusion The effect of sodium and potassium intake on CVD
morbidity and mortality in Western societies remains to be
established.
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Introduction
Observational and experimental data support an indepen-
dent, positive relationship between sodium intake and
blood pressure, most clearly in hypertensive populations
[1–3]. Potassium intake, on the other hand, has been
inversely related to blood pressure [3, 4]. Since hyperten-
sion is a strong predictor of cardiovascular disease (CVD),
especially stroke, inadequate intake of sodium and potas-
sium is likely to be associated with increased
cardiovascular morbidity and mortality [1]. Only recently,
population-based studies on dietary salt intake in relation to
CVD and non-cardiovascular events have received priority
[5]. Alderman et al. were among the ﬁrst to report an
increased risk of myocardial infarction with low urinary
sodium in treated hypertensive men [6]. In a subsequent
analysis of NHANES I data, an inverse association of
sodium intake with all-cause and cardiovascular mortality
was found [7]. Estimation of salt intake by 24-h dietary
recall and other methodological aspects of this analysis,
however, have been criticized [8–10]. Salt intake was not
signiﬁcantly related to coronary or all-cause mortality in
the large cohorts of the Scottish Heart Health Study [11]
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randomized trials showed no effect of long-term sodium
reduction on overall mortality, but this meta-analysis
included only 17 fatal events and should be interpreted
with caution [13]. He et al. showed that high sodium intake
was a strong risk factor for congestive heart failure in
overweight participants of the NHANES I follow-up study
[14], and also predictive for CVD and all-cause mortality
in this group [15]. Similarly, in a Finnish cohort, 24-h
urinary sodium excretion predicted mortality and risk of
coronary heart disease only in the presence of overweight
[16]. With regard to incidence of stroke, the Finnish study
showed no association with urinary sodium [16]. Stroke
mortality was neither predicted by dietary sodium intake in
MRFIT [12]. In the WHO Cardiovascular Diseases and
Alimentary Comparison (CARDIAC) Study in 24 coun-
tries, however, sodium intake appeared to be a risk factor
for stroke in men [17]. As a consequence of these incon-
sistent ﬁndings, there is currently no consensus as to the
cardiovascular risks of salt intake.
Tobian et al. demonstrated a lower risk of hemor-
rhagic stroke and mortality in hypertensive rats that had
been given potassium supplements, an effect that was
not mediated by blood pressure reduction [18]. Khaw
and Barrett-Connor conﬁrmed this independent protec-
tive effect of dietary potassium against stroke in humans
[19]. Also in the CARDIAC study [17], the Cardio-
vascular Health Study [20] and the Nurses Health Study
[21] the intake of potassium was inversely related to
risk of stroke. Data on dietary potassium in relation
to coronary and all-cause mortality in humans are
scanty. We examined the relationship of sodium and
potassium intake with cardiovascular events and all-
cause mortality in the older cohort of the population-
based Rotterdam Study.
Methods
The Rotterdam Study
This case–cohort analysis formed part of the Rotterdam
Study, a population-based prospective study among 7,983
men and women aged 55 years and older in the Nether-
lands [22]. The Medical Ethics Committee of the Erasmus
Medical Centre Rotterdam approved the study, and written
informed consent was obtained from all participants. From
August 1990 until June 1993, a trained research assistant
collected data on health, medication use, lifestyle, and risk
indicators for chronic diseases during a home interview.
Subjects were subsequently invited at the study centre for
clinical examination and assessment of diet.
Assessment of diet
Subjects were interviewed at the study centre by a trained
dietician, who used a validated, semi-quantitative food
frequency questionnaire [23]. The intake of total energy,
alcohol, macronutrients, and a large number of micronu-
trients was computed using Dutch food composition tables
[24]. No information on salt use was obtained and therefore
data on dietary sodium were considered unreliable for this
analysis.
Clinical examination
Height and body weight were measured with the subject
wearing indoor clothing without shoes. The body mass
index was computed as weight divided by height squared.
A trained research assistant measured sitting systolic and
diastolic blood pressure twice with a random-zero sphyg-
momanometer after a 5-min rest, and values were
averaged. Hypertension was deﬁned as a systolic blood
pressure ‡160 mmHg or diastolic blood pressure
‡95 mmHg or use of antihypertensive medication. Diabe-
tes mellitus was considered present when the subject
reported antidiabetic treatment, or when random or post-
load plasma glucose levels were 11.1 mmol/l or higher.
CVD was considered present in case of a veriﬁed history of
myocardial infarction, stroke, coronary bypass grafting, or
percutaneous transluminal coronary angioplasty. Serum
total and HDL cholesterol level (mmol/l) were determined
by standard laboratory methods [25].
Assessment of sodium and potassium excretion
Participants collected an overnight urine sample before
visiting the research centre and recorded collection times
on the jar. They were not aware that samples would be used
for estimation of electrolyte intake. At the research centre,
volumes were recorded, urines were swirled and 100 ml
samples were taken. Samples were stored in plastic tubes at
–20 C for future laboratory determinations. Urinary
sodium, potassium and creatinine determinations were
performed by Vitros
1 250 (formerly Ektachem 250)
Chemistry System (Johnson & Johnson, Ortho-Clinical
Diagnostics Inc., Rochester, New York). Determination of
electrolytes and creatinine were based on potentiometry
and enzymatic conversion, respectively. Urinary sodium
and potassium concentrations (mmol/l) were standardized
to 24-h values using recorded collection times and urinary
volumes (ml). In addition, urinary sodium/potassium ratio
was computed.
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123Follow-up procedures
The present analysis is based on follow-up data collected
from baseline (1990–1993) until 1 January 1998. Informed
consent for collection of follow-up data was obtained from
7,802 participants (98%). Information on vital status was
obtained at regular intervals from municipal population
registries. General practitioners (GPs) used a computerized
information system to record fatal and non-fatal events in
the research area (covering 85% of the cohort). In the
Netherlands, the GP forms the link to all specialized
medical care and clinical events are unlikely to be missed
by this follow-up procedure. Research physicians veriﬁed
all information on incident events using GP records and
hospital discharge letters. Events were coded indepen-
dently by two physicians according to the International
Classiﬁcation of Diseases, 10th revision (ICD-10) [26].
Coded events were reviewed by a medical expert in the
ﬁeld, whose judgment was considered deﬁnite in case of
discrepancies.
Myocardial infarction comprised ICD-10 code I21 and
stroke comprised ICD-10 codes I60-I67. Both fatal and non-
fatal incident events were recorded. For the present study,
only ﬁrst events were considered. Events followed by death
within 28 days were classiﬁed as fatal. CVD mortality
comprised fatal myocardial infarction, fatal stroke, sudden
cardiac death and other forms of fatal CVD (ICD-10 codes
I20-I25, I46, I49, I50, I60-I67, I70-I74, and R96).
Table 1 Baseline characteristics of the study population
Random sample Cases
Incident MI Incident stroke CVD mortality All-cause mortality
No. of subjects 1,448 206 181 217 795
In random sample (%) 31 31 28 29
Age (year) 69.2 (8.7) 71.0 (8.0) 74.0 (8.5) 76.8 (8.4) 76.9 (8.9)
Men (%) 41 62 45 51 49
Body mass index (kg/m
2) 26.4 (3.8) 26.3 (3.4) 26.0 (3.3) 26.2 (3.8) 25.7 (3.8)
Smoking status (%)
a
Current 23 29 28 23 26
Former 41 48 42 47 40
Never 36 23 29 29 35
Alcohol use (%) 81 74 80 71 73
Educational level (%)
a,b
Low 58 61 60 65 66
Intermediate 32 31 34 30 28
High 10 8 6 5 6
Serum cholesterol (mmol/l)
Total 6.6 (1.2) 6.3 (1.3) 6.5 (1.2) 6.6 (1.4) 6.3 (1.3)
HDL 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 1.2 (0.4) 1.3 (0.4)
Blood pressure (mmHg)
Systolic 140 (22) 145 (23) 149 (24) 146 (25) 145 (25)
Diastolic 74 (11) 74 (12) 75 (13) 73 (13) 73 (14)
Hypertension (%)
c 37 44 53 55 47
Diabetes mellitus (%)
d 10 21 22 26 21
History of CVD (%)
e 17 35 17 39 28
Values are means with standard deviations, or percentages; CVD, cardiovascular disease; MI, myocardial infarction
a Values not always add up to 100% due to rounding
b Highest achieved level of education; low, primary education, or less; intermediate, secondary general or vocational education; high, higher
vocational education, university
c Systolic blood pressure ‡160 mmHg or diastolic blood pressure ‡95 mmHg or use of antihypertensive medication
d Plasma glucose ‡11.1 mmol/l or treated with oral antidiabetes medication or insulin
e Veriﬁed history of cardiovascular disease, i.e. myocardial infarction, stroke, coronary bypass-grafting, or percutaneous transluminal coronary
angioplasty
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Of 7,129 subjects who visited the research centre, 6,605
adequately performed a timed overnight urine collection
for which collection times were recorded and volumes
exceeded 150 ml. Of those, 5,531 had blood pressure
readings and these subjects were eligible for the present
analysis. We followed a case–cohort approach for efﬁ-
ciency reasons. Assessment of urinary sodium, potassium
and creatinine excretion was performed in all subjects who
died (n = 795, including 217 cardiovascular deaths), and in
those who experienced a myocardial infarction (n = 206)
or stroke (n = 181) during follow-up. A random sample of
1,500 control subjects was taken from the eligible cohort
for assessment of electrolyte excretions. Urine samples
could not be retrieved for 52 of these subjects, and data on
urinary sodium, potassium and creatinine were thus
obtained in 1,448 subjects. Dietary data were available for
1,205 subjects (83%) of the random sample, 518 subjects
(65%) who died during follow-up, 157 subjects (72%) who
died from CVD, 170 subjects (83%) with an incident
myocardial infarction and 147 subjects (81%) with an
incident stroke. Reasons for missing dietary data were
participation in the pilot phase of the Rotterdam Study, low
cognitive function, and logistic reasons, as described in
more detail elsewhere [23]. Of the random sub-cohort
(n = 1,448), 783 subjects (54%) were free of CVD and
hypertension at baseline.
Data analysis
Pearson correlations were computed to examine inter-
relationships between urinary and dietary measures of
electrolyte intake and associations with total energy intake.
The association of urinary and dietary electrolytes with
incident myocardial infarction, incident stroke, cardiovas-
cular mortality and all-cause mortality was evaluated in a
case–cohort design with standard Cox proportional-hazards
models with modiﬁcation of the standard errors based on
robust variance estimates [27, 28]. We used the method
according to Barlow in which the random cohort is
weighted by the inverse of the sampling fraction from the
source population. Members of the random cohort are
included from baseline until failure or censoring, whereas
cases outside the cohort are included at the time of their
event. For the Cox models we used Proc MI and Proc
MIanalyze, in conjunction with Proc Phreg (SAS 8.2).
Relative risks (RR) with 95% conﬁdence intervals
(95%-CI) were computed per 1 standard deviation increase
in urinary sodium (mmol/24 h), urinary potassium (mmol/
24 h) and dietary potassium intake (mg/day), and per 1 unit
increase in urinary sodium/potassium ratio. Two-sided P-
values below 0.05 were considered statistically signiﬁcant.
Adjustment was made for age, sex and, in urinary analyses,
for 24-h urinary creatinine excretion (model 1). In a second
analysis (model 2), additional adjustment was made for
body mass index (kg/m
2), smoking status (current, past, or
Table 2 Baseline urinary excretions and dietary intakes of Dutch men and women aged 55 years and over: The Rotterdam Study
Random subcohort Cases
Incident MI Incident stroke CVD mortality All-cause mortality
Urinary excretion
a
Volume (l/24 h) 1.4 (0.6) 1.4 (0.6) 1.4 (0.6) 1.3 (0.6) 1.3 (0.6)
Sodium (mmol/24 h) 117 (69) 124 (68) 115 (72) 99 (61) 107 (66)
Potassium (mmol/24 h) 45 (22) 47 (22) 45 (23) 44 (24) 44 (22)
Sodium/potassium 2.8 (1.5) 2.7 (1.3) 2.7 (1.3) 2.5 (1.4) 2.6 (1.6)
Creatinine (mmol/24 h) 9.2 (4.9) 9.8 (4.7) 8.4 (4.4) 8.1 (4.7) 8.1 (4.4)
Sodium/creatinine 13.8 (6.6) 13.6 (6.1) 14.6 (7.1) 14.0 (8.0) 14.8 (7.9)
Potassium/creatinine 5.4 (2.2) 5.3 (2.1) 5.8 (2.1) 6.1 (2.6) 6.1 (2.5)
Dietary intake
b
Total energy (mJ/day) 8.3 (2.1) 8.6 (2.2) 8.4 (2.2) 8.3 (2.0) 8.5 (2.2)
Saturated fat (g/day) 32 (12) 34 (13) 34 (13) 33 (13) 34 (12)
Calcium (g/day) 1.1 (0.4) 1.1 (0.4) 1.1 (0.4) 1.1 (0.5) 1.1 (0.4)
Sodium (g/day)
c 2.2 (0.7) 2.3 (0.6) 2.2 (0.6) 2.2 (0.7) 2.2 (0.7)
Potassium (g/day) 3.6 (0.8) 3.7 (0.8) 3.6 (0.8) 3.6 (0.9) 3.6 (0.9)
Values are means with standard deviations; CVD, cardiovascular disease; MI, myocardial infarction
a Based on one timed overnight urine sample
b Dietary data were available for 1,205 subjects of the random sample (83%), 170 MI cases (83%), 147 stroke cases (81%), 157 CVD deaths
(72%), and 518 deaths from any cause (65%)
c Only from foods, discretionary sources not included
766 J. M. Geleijnse et al.
123never), diabetes mellitus (yes/no), use of diuretics (yes/no),
and highest completed education (three categories). In a
third analysis (model 3), dietary confounders were addi-
tionally adjusted for, i.e. daily intake of total energy (kJ),
alcohol (g), calcium (g), and saturated fat (g). In the
analysis for urinary sodium we additionally included uri-
nary potassium in this model, and vice versa.
Analyses were repeated after exclusion of subjects with
a history of CVD or hypertension to avoid biased risk
estimates due to intentional dietary changes. Within this
sub-cohort, a predeﬁned stratiﬁed analysis of urinary
sodium and urinary sodium/potassium ratio with cardio-
vascular and all-cause mortality was performed in subjects
with a high body mass index (i.e., ‡25 kg/m
2), using model
3.
Also in the sub-cohort free of CVD and hypertension,
the distribution of 24-h urinary sodium excretion was
divided into quartiles to be able to examine the relationship
with all-cause mortality at extreme intakes. Quartiles of
urinary sodium (cut-off levels: 66, 105 and 151 mmol/
24 h) were entered categorically into the fully adjusted
model (model 3), using the lower quartile as the reference.
Results
The study had a median follow-up of 5.5 years. Baseline
characteristics of the study population are shown in
Table 1. Randomly selected controls (n = 1,448) were
expectedly healthier at baseline than cases, as indicated by
a lower prevalence of hypertension, diabetes, and CVD.
Baseline urinary excretions and dietary intakes are
presented in Table 2. In the random sample, 24-h urinary
sodium excretion estimated from overnight urine collection
was 117 mmol (i.e., 2.7 g/day, which corresponds to a
NaCl intake of 6.8 g/day). Urinary potassium excretion
was 45 mmol/24 h (1.8 g/day), which was half the amount
estimated by food frequency questionnaire (3.6 g/day). The
correlation between urinary and dietary potassium was 0.21
(P\0.001).
RR for cardiovascular events and all-cause mortality per
1-SD increase in 24-h urinary sodium are presented in
Table 3. Urinary sodium was not signiﬁcantly associated
with incident myocardial infarction, incident stroke, or
overall mortality. For CVD mortality, however, a border-
line signiﬁcant inverse association was observed
(RR = 0.77 (0.60–1.01) per 1-SD, model 3) but the rela-
tionship was attenuated after excluding subjects with a
history of CVD or hypertension (RR = 0.83 (0.47–1.44)
per 1-SD, model 3). In subjects initially free of CVD, the
risk of all-cause mortality was also examined across
quartiles of 24-h urinary sodium (median values: 45, 87,
125 and 190 mmol, respectively). RR in consecutive
quartiles, using the lower quartile as the reference, were
0.80 (0.43–1.49), 0.66 (0.34–1.27) and 0.98 (0.54–1.78),
respectively (model 3). In a subgroup analysis of CVD free
subjects with a body mass index ‡25 kg/m
2, the association
of urinary sodium with CVD mortality or all-cause mor-
tality was neither statistically signiﬁcant (RR = 0.91 (0.44–
1.89) and RR = 1.19 (0.86–1.66) per 1-SD, respectively;
model 3).
Findings for potassium are presented in Table 4. Urinary
potassium tended to be positively associated with incident
CVD events or mortality, especially in subjects who were
initially free of CVD and hypertension. After full adjust-
ment for confounders (model 3), however, none of these
associations were statistically signiﬁcant. Urinary potas-
sium did neither predict all-cause mortality. For dietary
potassium, similar results were obtained except for risk of
all-cause mortality that was signiﬁcantly reduced both in
Table 3 Relative risk of urinary sodium with cardiovascular events
and all-cause mortality in Dutch men and women aged 55 years and
over
All subjects
a Subjects initially free
of CVD and hypertension
a
Incident MI
RR, model 1
b 1.13 (0.95–1.34) 1.04 (0.75–1.43)
RR, model 2
c 1.16 (0.98–1.39) 1.07 (0.77–1.50)
RR, model 3
d 1.19 (0.97–1.46) 1.14 (0.77–1.69)
Incident stroke
RR, model 1 1.09 (0.89–1.33) 1.16 (0.84–1.61)
RR, model 2 1.09 (0.87–1.35) 1.15 (0.81–1.62)
RR, model 3 1.08 (0.80–1.46) 1.02 (0.66–1.58)
CVD mortality
e
RR, model 1 0.74 (0.60–0.91) 0.84 (0.59–1.22)
RR, model 2 0.83 (0.68–1.02) 0.95 (0.66–1.39)
RR, model 3 0.77 (0.60–1.01) 0.83 (0.47–1.44)
All-cause mortality
RR, model 1 0.90 (0.81–1.02) 1.00 (0.83–1.20)
RR, model 2 0.96 (0.84–1.09) 1.10 (0.91–1.34)
RR, model 3 0.95 (0.81–1.12) 1.12 (0.86–1.46)
RR, Relative risk with 95% conﬁdence interval per standard deviation
increase in urinary sodium (mmol/24 h), obtained by Cox propor-
tional hazard analysis
a Number of cases and subjects in random sample given in Table 1
b Ajusted for age, sex and (for urinary sodium) 24-h urinary creati-
nine excretion
c As model 1, with additional adjustment for body mass index,
smoking status, diabetes, use of diuretics, highest completed
education
d As model 2, with additional adjustment for daily intake of total
energy, alcohol, calcium, saturated fat and 24-h urinary potassium
excretion
e Cardiovascular mortality comprises fatal myocardial infarction,
fatal stroke, sudden cardiac death and other forms of fatal CVD
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subjects initially free of CVD and hypertension (RR = 0.71
(0.51–1.00), model 3).
Data for urinary sodium/potassium ratio (Table 5)
showed no relationship with CVD events and mortality.
When restricting this analysis to CVD free subjects with a
body mass index ‡25 kg/m
2, urinary sodium/potassium
ratio was signiﬁcantly associated with all-cause mortality
(RR = 1.19 (1.02–1.39) per unit, model 3), but not with
CVD mortality (RR = 0.86 (0.60–1.25)).
Discussion
In an unselected population of older Dutch subjects we
found no consistent association of urinary sodium and
potassium with CVD events or mortality. Dietary potas-
sium estimated by food frequency questionnaire, however,
was associated with a lower risk of all-cause mortality.
Urinary sodium/potassium ratio was positively associated
with mortality risk, but only in overweight subjects without
CVD and hypertension at baseline.
Electrolyte intake was assessed from one overnight
urine collection, which provides a crude estimate of short-
term intake [29, 30]. Luft et al. examined the utility of
nocturnal sodium excretion under controlled intake condi-
tions, in which daily sodium intake was randomly varied
[31]. In that study, on a randomly selected day, both 24-h
and nocturnal sodium excretion estimated the daily intake
reasonably well. Nevertheless, it is likely that misclassiﬁ-
cation has attenuated the relationships with CVD events
and mortality in our study. Incomplete urine collection was
partly adjusted for by adding urinary creatinine excretion to
the multivariate models. In addition, we examined the
urinary sodium/potassium ratio, which is less inﬂuenced by
incomplete urine collection. To exclude bias due to dietary
changes, we repeated all analyses in a subgroup without
CVD or hypertension at baseline.
Salt intake was not consistently related to CVD or
mortality in our study. An explanation for the absence of a
positive relationship, apart from regression dilution bias,
may be the relatively narrow range of salt intake in the
Netherlands and the lack of contrast in exposure within a
single population. An increased risk of mortality was
Table 4 Relationship of urinary and dietary potassium with cardiovascular events and all-cause mortality in Dutch men and women aged
55 years and over
All subjects
a Subjects initially free of CVD and hypertension
a
Urinary excretion
(mmol/24 h)
Dietary intake
(mg/day)
Urinary excretion
(mmol/24 h)
Dietary intake
(mg/day)
Incident MI
RR, model 1
b 1.10 (0.89–1.35) 0.98 (0.85–1.13) 1.15 (0.84–1.59) 1.14 (0.85–1.54)
RR, model 2
c 1.16 (0.94–1.43) 0.94 (0.81–1.09) 1.25 (0.94–1.74) 1.07 (0.78–1.46)
RR, model 3
d 1.11 (0.87–1.43) 0.90 (0.65–1.24) 1.22 (0.79–1.87) 1.32 (0.65–2.67)
Incident stroke
RR, model 1 1.09 (0.87–1.36) 0.99 (0.84–1.17) 1.12 (0.79–1.60) 1.07 (0.79–1.43)
RR, model 2 1.12 (0.89–1.42) 0.99 (0.84–1.16) 1.15 (0.77–1.71) 1.20 (0.86–1.68)
RR, model 3 1.17 (0.86–1.58) 1.02 (0.71–1.46) 1.11 (0.61–2.04) 1.06 (0.50–2.29)
CVD mortality
e
RR, model 1 1.13 (0.90–1.41) 0.97 (0.82–1.14) 1.63 (1.14–2.33) 1.23 (0.83–1.84)
RR, model 2 1.14 (0.92–1.42) 0.95 (0.81–1.12) 1.66 (1.08–2.56) 1.19 (0.78–1.83)
RR, model 3 1.23 (0.94–1.60) 0.97 (0.72–1.31) 1.45 (0.84–2.54) 1.43 (0.67–3.03)
All-cause mortality
RR, model 1 1.04 (0.91–1.18) 0.91 (0.82–1.01) 1.06 (0.88–1.28) 0.95 (0.78–1.17)
RR, model 2 1.06 (0.86–1.31) 0.89 (0.80–0.99) 1.06 (0.86–1.31) 0.90 (0.73–1.12)
RR, model 3 1.08 (0.91–1.28) 0.78 (0.65–0.94) 0.95 (0.71–1.26) 0.71 (0.51–1.00)
RR, Relative risk with 95% conﬁdence interval per standard deviation increase in urinary or dietary potassium, obtained by Cox proportional
hazard analysis
a Number of cases and subjects in random sample given in Table 1
b Ajusted for age, sex and (for urinary potassium) 24-h urinary creatinine excretion
c As model 1, with additional adjustment for body mass index, smoking status, diabetes, use of diuretics and highest completed education
d As model 2, with additional adjustment for daily intake of total energy, alcohol, calcium, saturated fat and 24-h urinary sodium excretion
e Cardiovascular mortality comprises fatal myocardial infarction, fatal stroke, sudden cardiac death and other forms of fatal CVD
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with 24-h urinary excretions close to 200 mmol (RR =
1.56 per 100 mmol) [16]. However, this could not be
conﬁrmed in our analysis of quartiles of sodium intake in
relation to overall mortality (RR = 0.98 in CVD free sub-
jects with median sodium excretion of 190 mmol/24 h).
The absence of a relationship between salt intake and
mortality in our study corroborates the ﬁndings from the
large Scottish Heart Health Study among almost 12,000
middle-aged subjects with 24-h urine samples [11]. Fol-
low-up data of the MRFIT trial neither showed a
relationship between dietary sodium intake estimated by
24-h recall and cardiovascular events or mortality [12].
However, other prospective epidemiological studies do
suggest that sodium intake is related to morbidity and
mortality [6, 7, 15, 16], although this may be conﬁned to
speciﬁc subgroups with overweight, hypertension or high
salt intake. In overweight subjects, we did ﬁnd a positive
relationship between urinary sodium/potassium ratio and
overall mortality (19% increase in risk per unit change in
sodium/potassium ratio).
A protective effect of potassium intake against stroke, as
previously reported [19–21], could not be conﬁrmed by our
data. We neither observed an association between potas-
sium intake and coronary events. Long-term rather than
short-term intake may be relevant and therefore we esti-
mated habitual potassium intake during the preceding year
by food frequency questionnaire. Mortality risk was
reduced by 29% per 1-SD increase in dietary potassium,
although only in subjects initially free of CVD and
hypertension. Except for misclassiﬁcation, although less
likely than for sodium, we have no explanation for the
absent relationship between potassium intake and CVD
events. In the Scottish Heart Health Study, 24-h urinary
potassium excretion was inversely related to all-cause
mortality and coronary events [11]. Data on potassium
intake in relation to mortality, however, are sparse and
more prospective population-based studies are needed to
draw conclusions. Preferably, the effect of dietary potas-
sium on CVD should be examined in a randomized trial.
Prolonged differences in blood pressure of 5 mmHg
may result in a one-third reduction in stroke and one-ﬁfth
reduction in coronary events [32]. Meta-analysis of ran-
domized controlled trials showed that sodium reduction
around 2 g per day could lower blood pressure by 2–
3 mmHg, with the effect being twice as large in hyper-
tensives [33]. The World Health Organization recommends
that people should consume less than 5 g of salt (i.e. 2 g of
sodium) per day in order to prevent CVD [34]. From this
and other epidemiological studies we conclude that effect
of dietary salt on clinical cardiovascular endpoints and
overall mortality within the range of intake commonly
observed in Western countries has not yet been established.
More research is needed to settle the discussion regarding
this major public health issue.
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